Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults

Brad Spellberg and Benjamin A. Lipsky
1 Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, and 2 David Geffen School of Medicine at UCLA, Los Angeles, California; 3 VA Puget Sound Health Care System, and 4 University of Washington, Seattle

The standard recommendation for treating chronic osteomyelitis is 6 weeks of parenteral antibiotic therapy. However, oral antibiotics are available that achieve adequate levels in bone, and there are now more published studies of oral than parenteral antibiotic therapy for patients with chronic osteomyelitis. Oral and parenteral therapies achieve similar cure rates; however, oral therapy avoids risks associated with intravenous catheters and is generally less expensive, making it a reasonable choice for osteomyelitis caused by susceptible organisms. Addition of adjunctive rifampin to other antibiotics may improve cure rates. The optimal duration of therapy for chronic osteomyelitis remains uncertain. There is no evidence that antibiotic therapy for 4–6 weeks improves outcomes compared with shorter regimens. In view of concerns about encouraging antibiotic resistance to unnecessarily prolonged treatment, defining the optimal route and duration of antibiotic therapy and the role of surgical debridement in treating chronic osteomyelitis are important, unmet needs.

Chronic osteomyelitis is an infection of bone that does not result from acute hematogenous seeding or penetrating injury and usually occurs by contiguous spread and has been present for several weeks. Perhaps the earliest known case of chronic osteomyelitis dates to the Permian era, in an unfortunate dimetrodon that developed infection in a fractured spinal shaft [1]. This 250 million-year-old case highlights 3 of the problems that remain common when managing chronic osteomyelitis: (1) the diagnosis was established only after bone (or rather fossil) biopsy; (2) no cultures were performed to define the etiologic organism; and (3) treatment (if any) was probably delayed and certainly ineffective.

In the antibiotic era, chronic osteomyelitis remains difficult to treat and has a high rate of relapse after apparently successful treatment [2–4]. Indeed, case reports have described relapses of osteomyelitis up to 80 years after the initial presentation [5–8]. These relapses are probably due to bacterial evasion of host defenses by hiding intracellularly and as nonreplicating persisters within biofilm [9]. Because of these concerns, clinicians often treat chronic osteomyelitis with antibiotic therapy that is parenteral, high dose, and prolonged. This standard recommendation derives largely from the belief that it takes 3–4 weeks for infected bone to revascularize as well as from experience treating children with acute osteomyelitis. It was codified by a seminal case series by Waldvogel et al [10–12] in 1970. The authors stated that “osteomyelitis is rarely controlled without the combination of careful, complete surgical debridement and prolonged (4–6 weeks) parenteral antibiotic therapy at high dosage.” However, this case series was retrospective and uncontrolled, and it included a heterogeneous patient population, and parenteral penicillin was the predominant antibiotic administered.

What have we learned about treating chronic osteomyelitis in the past few decades? Previous reviews of this topic have concluded that available literature is inadequate to determine the best agent, route, or duration.
of antibiotic therapy [13–15]. Undeterred, we set out to review studies published since 1970 in an attempt to address 4 fundamental questions regarding treatment of chronic osteomyelitis in adults: (1) Are certain antibiotic agents preferred choices? (2) Are oral regimens acceptable for selected cases? (3) For how long should antibiotic therapy be given? and (4) Is surgical debridement always necessary for cure? We searched PubMed and ScienceDirect for the term “osteomyelitis” from 1970 to 2011, and EBSCO, Web of Science, and Google Scholar for any types of studies on treatment of chronic osteomyelitis in adults. We reviewed all articles if they, or at least their abstracts, were in English.

PHARMACOLOGY OF OSTEOMYELITIS THERAPY

Parenteral Antibiotic Agents

β-Lactam antibiotics (penicillins, cephalosporins, and carbapenems) penetrate bone at levels ranging from ~5% to 20% of those in serum (Table 1). Nevertheless, because serum levels of
parenterally delivered β-lactam antibiotics are so high, absolute bone levels likely exceed target minimum inhibitory concentrations (MICs) of etiologic bacteria in most cases. In contrast, because serum levels of oral β-lactam agents are <10% of those of parenteral agents, oral dosing is unlikely to achieve adequate bone levels. β-lactam penetration is higher in infected than in uninfected bone [31, 33, 34], but it is markedly decreased in patients with peripheral vascular disease [29, 46] and is probably low in sequesta.

Similar to β-lactam antibiotics, vancomycin penetrates bone poorly [24] (Table 1). However, when serum levels of vancomycin were >35 μg/mL, its penetration of sternal bone (~30% of serum concentrations) was better than in axial skeletal bone [47, 48]. Daptomycin also penetrates bone relatively poorly (Table 1), but levels are probably high enough to exceed the target MICs for bacteria in bone [25, 49].

Oral Antibiotic Agents
Recent studies demonstrate that oral antibiotics can achieve levels in bone that exceed MICs of targeted organisms (Table 2). In particular, fluoroquinolones, linezolid, and trimethoprim have been found to achieve bone concentrations at ~50% of serum [52, 53, 55] (Table 2). Although the sulfamethoxazole component of trimethoprim-sulfamethoxazole (TMP-SMX) has poorer penetration (10%–20%), its serum concentrations are 20-fold higher than those of trimethoprim, so its bone concentrations generally exceed the MICs of susceptible organisms. Because TMP-SMX exhibits concentration-dependent killing [88–90], higher doses (ie, 7–10 mg/kg trimethoprim, or 2 double-strength tablets twice per day) may result in greater efficacy when treating chronic osteomyelitis. The lack of a fixed 1:5 ratio of concentrations of trimethoprim and sulfamethoxazole at the site of infection does not hinder their synergy [91].

Other orally available agents to which many community-associated strains of methicillin-resistant Staphylococcus aureus (MRSA) are susceptible are doxycycline and clindamycin [92–95]. Doxycycline penetrates, and discolors, teeth [96] and bone, but concentrations range from as low as 2% in axial skeletal bone [62, 63] to as high as 86% in mandibular bone [61] (Table 2). Clindamycin reliably penetrates bone at levels of approximately 40%–70% of serum [64–66] (Table 2), and its achievable bone levels should exceed the MICs of susceptible MRSA isolates.

An oral antibiotic option for treatment of anaerobic osteomyelitis is metronidazole, which penetrates bone at concentrations approximating those in serum [67, 68] (Table 2). In case reports, metronidazole has been found to cure anaerobic osteomyelitis, including as salvage therapy after failure of clindamycin or cephalosporin therapy [97–100]. Rifampin also achieves concentrations in bone near, or exceeding, those in serum [69, 82, 83, 101] (Table 2). Because serum concentrations of rifampin increase dramatically at doses >450 mg/d [102, 103], prescribing 600 mg once daily should suffice. Finally, both fusidic acid [70, 71, 104] and fosfomycin [72] penetrate bone extremely well, at concentrations in excess of target MICs (Table 2).

In summary, oral options for the treatment of chronic osteomyelitis based on pharmacokinetic considerations include fluoroquinolones, TMP-SMX, or fosfomycin for susceptible gram-negative bacilli, and TMP-SMX, clindamycin, and linezolid for susceptible gram-positive infections. Rifampin and fusidic acid are reasonable adjunctive agents for combination therapy.

ANIMAL MODELS OF CHRONIC OSTEOMYELITIS
Standard models of chronic staphylococcal osteomyelitis include those in which infection is induced in long bones of rabbits and rats [2]. In such models, in vitro kill curves do not reliably predict in vivo efficacy. For example, in both models, rifampin was more active in vivo than clindamycin, azithromycin, vancomycin, trimethoprim, and ciprofloxacin, and it was synergistic in vivo with each of these agents as well as with cephalothin, despite being either indifferent or antagonistic to all of them in vitro [82, 101, 105]. In addition, ciprofloxacin monotherapy had minimal in vivo effect when treating infection caused by S. aureus strains susceptible to ciprofloxacin in vitro [82]. Thus, rifampin exhibits synergistic activity in vivo with myriad antibiotics, and clinicians should be cautious about using ciprofloxacin monotherapy to treat osteomyelitis caused by S. aureus, regardless of the MIC of the isolate.

NONRANDOMIZED CLINICAL TRIALS
Parenteral Therapy
In nonrandomized studies of adults with chronic osteomyelitis, 4–6 weeks of parenteral β-lactam antibiotic therapy has cured 60%–90% of cases (Table 3). The varying cure rates may be related to variable diagnostic criteria, use of concomitant surgical debridement (specifically reported in only 2 studies [107, 108]), or duration of follow-up. In multiple studies, the cure rates of infections caused by Pseudomonas were lower than those for other pathogens [108, 109, 112].

Vancomycin achieves low cure rates for chronic osteomyelitis [117, 121, 122]. In patients receiving outpatient parenteral antibiotic therapy of osteomyelitis, treatment of S. aureus infection with vancomycin (compared with β-lactam agents) had an odds ratio (OR) for recurrence of 2.5 by multivariate analysis [121, 122]. Other independent risk factors for recurrence included the presence of diabetes mellitus (OR, 1.9), peripheral vascular disease (OR, 7.9), and infection with Pseudomonas (OR, 2.2).

In a salvage study of patients with MRSA osteomyelitis that had failed to respond to previous therapy, all 9 patients who were treated with daptomycin had clinical resolution of their
| Drug            | Patients, No. | Dose     | Route   | Serum Level, Mean (Range), µg/mL | Bone Level, Mean (Range), µg/g | Serum-Bone Ratio, % | Reference |
|-----------------|---------------|----------|---------|---------------------------------|--------------------------------|--------------------|-----------|
| Ciprofloxacin   | 7             | 500 mg   | Oral    | 1.4 (0.4–2)                     | 0.4 (0.2–0.9)                  | 30                 | [50]      |
|                 | 7             | 750 mg   | Oral    | 2.6 (0.9–4)                     | 0.7 (0.2–1.4)                  | 27                 |           |
|                 | 6             | 500 mg   | Oral    | 2.0 (0.9–3)                     | 0.7 (0.2–1.4)                  | 35                 |           |
|                 | 4             | 750 mg   | Oral    | 2.9 (1–6)                       | 1.4 (0.6–2.7)                  | 48                 |           |
| Ciprofloxacin   | 20            | 200 mg   | Intravenous | NA                      | 2 (medullary)                  | 66                 | [51]      |
|                 |               |          |         |                                 | 1.4 (cortical)                 | 47³                |           |
| Ciprofloxacin   | 15            | 200 mg   | Intravenous | NA                      | 0.1–0.9                        | 3–30³              | [52]      |
| Levofloxacin    | 9             | 500 mg   | Intravenous | 8                      | 6 (medullary)                  | 75                 | [53]      |
|                 |               |          |         |                                 | 3 (cortical)                   | 38                 |           |
| Enoxacin        | 24            | 400 mg   | Oral or | 2.4                             | 0.9                            | 37.5               | [55]      |
|                 | 7             |          | Intravenous | 1.3³                  |                                | 55                 |           |
| Moxifloxacin    | 10            | 400 mg   | Intravenous | 4.9                    | 1.9 (medullary)                | 39                 | [56]      |
|                 | 10            | 400 mg   | Oral    | 3.7                             | 1.8 (medullary)                | 49                 |           |
| Linezolid       | 13            | 600 mg   | Oral    | NA                              | 4                              | 40³                | [57]      |
| Linezolid       | 12            | 600 mg   | Oral    | NA                              | 9                              | 51³                | [58]      |
| Linezolid       | 10            | 600 mg   | Oral    | 23                              | 8.5                            | 37                 | [59]      |
| TMP-SMX         | 14            | 1 DS tablet twice daily for 2 d | Oral | 7.4/143                         | 3.7/19                         | 50/15              | [60]      |
| Doxycycline     | 6             | 200 mg   | Intravenous | NA                      | 2.6                            | 86⁶                | [61]      |
| Doxycycline     | 25            | 200 mg   | Intravenous | NA                      | 0.2                            | 6⁴                 | [62]      |
| Doxycycline     | 34            | 200 mg   | Intravenous | 6                      | 0.13                           | 2                  | [63]      |
| Clindamycin     | 13            | 600 mg   | Intravenous or intramuscular | NA                  | 5                              | 67³                | [64]      |
| Clindamycin     | 27            | 300 mg   | Intramuscular | 7.33                | 2.63                           | 40                 | [65]      |
| Clindamycin     | 23            | 600 mg   | Intravenous | 8.5                      | 3.8                            | 45                 | [66]      |
| Metronidazole   | 16            | 500 mg   | Intravenous | NA                      | 14                             | 100⁴              | [67]      |
| Metronidazole   | 17            | 1500 mg  | Intravenous | 34                    | 27                             | 79                 | [68]      |
| Rifampin        | 32            | 300 mg   | Intravenous | 2                      | 5 (1.4–8.8)                    | >100⁵              | [69]      |
| Fusidic acid in infected bone ¹ | 15 | 500 mg 3 times daily | Oral | NA | 7.3 (1.7–14.9) | | [70] |
|                 | 14            | 1 g 3 times daily | Oral | NA | 9.8 (3.4–14.8) | | [70] |
| Fusidic acid in uninfected bone | 9 | 500 mg 3 times daily for 5 d | Oral | 27 (2–109) | 12 (1–40) | 44 | [70] |
|                 | 15            | 500 mg 3 times daily for 6–10 d | Oral | 45 (5–166) | 21 (2–75) | 47 |           |
|                 | 14            | 500 mg 3 times daily for >10 d | Oral | 27 (3–59) | 25 (3–79) | 93 |           |
| Fusidic acid ³ ¹ | 30 | 2 or 3 g/d | Oral | 15–210 | 1.5–54 | NA | [71] |
| Fosfomycin      | 19            | 10 g once, then 5 g 3 times daily | Intravenous | NA | 13.5 (uninfected) | | [72] |
|                 | 9             | 100 mg/kg | Intravenous | 377 ± 73 | 96 ± 15 | 25 | [73] |

Abbreviations: NA, not applicable; TMP-SMX, trimethoprim-sulfamethoxazole.

¹ Levels in infected (osteomyelitic) bone after debridement.
² Assuming peak serum levels of 3 µg/mL for ciprofloxacin [74], 20 µg/mL for linezolid [75, 76], 3 µg/mL for doxycycline [77], 8 µg/mL for clindamycin [66, 78, 79], and >14 µg/mL for metronidazole [80, 81].
³ Concordant animal data [79, 82, 83, 84, 85, 86, 87].
⁴ Infected bone refers to levels measured in osteomyelitic bone that was debrided.
### Table 3. Cure Rates in Nonrandomized Clinical Trials of Parenteral Agents for Chronic Osteomyelitis With or Without Infected Prosthesis in Adults

| Drug | Dose (Duration) | Follow-up | Cure, a No. of Patients (%) | Comment | Reference |
|------|-----------------|-----------|-----------------------------|---------|-----------|
| Cefazolin | 2–4 g/d (mean, 35 d) | Mean, 34 mo | 15/16 (94) | 4/5 diabetic foot infections cured, all with debridement | [23] |
| Cefotaxime | 1 g/8 h (duration unclear) | 0–17 mo | 24/27 (89) | Cure defined as disease “arrested” | [106] |
| Cefotaxime | 2–16 g/d (mean, 23 d) | ? | 25/32 (78) | Cure with surgery in 21/24, without surgery in 4/8 | [107] |
| Imipenem | 0.1–1 g/6 h (mean, 5 wk) | Mean, 11 mo | 20/34 (59) | Pseudomonas main cause of failure: 10/14 cured | [108] |
| Ceftazidime | 2 g/12 h (2–16 wk) | >12 mo | 9/15 (60) | 12 cases caused by Pseudomonas | [109] |
| Cefotaxime | 2 g/6 h (mean, 40 d) | 6 mo | 40/55 (73) | ... | [110] |
| Aztreonam | 2 g/6 h (14–55 d) | 4–18 mo | 11/11 (100) | All infections due to gram-negative rods | [111] |
| Aztreonam | 2 g/8 h (mean, 40 d) | Mean, 6 mo | 13/18 (72) | All due to Pseudomonas | [112] |
| (Cefsulodin or piperacillin or imipenem) + (ofloxacin or pefloxacin or ciprofloxacin) | Varying doses (≤4 mo) | Mean, 3 y | 11/15 (73) | All due to Pseudomonas | [113] |
| Ampicillin-sulbactam | 1.5 g/6 h (mean, 41 d) | ? | 42/49 (86) | All patients diabetic; 14 patients had amputations | [114] |
| Ticarcillin-clavulanate | 9–12 g/d (mean, 6 wk) | ? | 39/50 (78) | ... | [115] |
| Cefepime + (ofloxacin or ciprofloxacin) | Cefepime: 2 g twice daily (4 wk); ofloxacin: 200 mg 3 times daily (3–9 mo); ciprofloxacin: 500–750 mg twice daily (3–9 mo) | ? | 22/28 (79) | Mixture of chronic osteomyelitis and prosthetic implant infections; quinolones given intravenously at first and then by mouth | [116] |
| Vancomycin | Variable dosing (mean, 6 wk) | ? | 44/81 (54) | 62 patients underwent debridement; 30 had infected prostheses, 27 had removal | [117] |
| β-Lactam or vancomycin | Variable for β-lactam; vancomycin: 1 g/12 h (mean, 66 d for MRSA, 55 d for MSSA) | >12 mo | 30/35 (86) | Relapses: 0/15 patients treated with rifampin vs 5/20 treated without rifampin; all started with intravenous therapy; many received subsequent oral therapy with various agents | [118] |
| Daptomycin | 6 mg/kg/d | ? | 8/9 (89) | Infection resolved in all patients, relapse in 1 patient; salvage therapy | [119] |
| Daptomycin | 6 mg/kg/d (median, 38 d) | Mean, 9 wk | 16/25 (64) | 16 resolved, 8 improved | [49] |
| Daptomycin | Variable dosing (mean, 35 d) | Mean, 76 d | 42/67 (63) | Failures more likely with no debridement (24% vs 5%) and with doses <4 mg/kg/d (35% vs 12%) | [120] |

Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive S. aureus.

a Definitions of cure varied among the trials.
infection by the end of therapy, but 1 patient subsequently relapsed [119]. Larger retrospective studies of daptomycin treatment of chronic osteomyelitis have reported cure rates of 65%–75% [49, 120]. Case reports suggest the potential for quinupristin-dalfopristin and tigecycline to cure chronic osteomyelitis, but clinical data are limited [123–126].

**Oral Therapy: Fluoroquinolones**

There are more studies of fluoroquinolones for treating chronic osteomyelitis than of all other antibiotic classes (Table 4). Cross-study comparisons are difficult because of the varied criteria for enrollment, utilization of debridement, antibiotic dosing regimens, duration of follow-up, and definitions of cure. Nevertheless, we draw several general inferences from these studies.

1. Most studies reported cure rates of 60%–80% [129, 138, 139].
2. Cure rates were similar to debridement rates (when reported), but because none of the studies specifically reported cure rates of patients who did and did not undergo debridement, the benefit of debridement can only be inferred.
3. The majority of failures occurred in patients infected with *Pseudomonas*, and to a lesser extent, patients infected with *S. aureus*.
4. Therapy was typically given for 12–16 weeks, and at doses higher than those used for most other infections (eg, ciprofloxacin at ≥1500 mg/d), but it is not possible from the available data to conclude that this high-dose and prolonged treatment is necessary.

**Oral Therapy: Other Agents**

Although it should never be used alone for treating osteomyelitis, several reports have shown that rifampin improves treatment outcomes when used in combination with other antibiotics (Table 4). Norden et al [101] added rifampin to therapy with a β-lactam, doxycycline, or an aminoglycoside in 14 patients, most of whom had had osteomyelitis for >15 years and in whom multiple prior treatment attempts had failed. Overall, 50% were cured, and patients in whom treatment failed were all infected with gram-negative bacilli resistant to the non-rifampin agent. In another study of patients with *S. aureus* osteomyelitis, there were no relapses among 15 patients in whom rifampin was added to treatment with various other antibiotic agents compared with 5 relapses among 20 patients who did not receive adjunctive rifampin [118]. Finally, adjunctive rifampin improved cure rates of prosthetic joint infections in 2 recent studies [143, 144].

A large compassionate-use data set demonstrated that linezolid treatment cured 60% of the 89 patients with chronic osteomyelitis [145]. In several case reports, clindamycin therapy successfully eradicated anaerobic osteomyelitis [153–155]. Likewise, among 12 patients with chronic (primarily staphylococcal) osteomyelitis treated with clindamycin at very low doses (75–150 mg/6 h), 5 patients were cured and another 5 showed substantial improvement [146].

TMP-SMX is second only to ciprofloxacin in the number of published studies of its effectiveness for treatment of chronic osteomyelitis. Saengnipanthkul et al [148] reported a 45% cure rate using standard dose TMP-SMX (1 double-strength tablet twice daily) to treat 66 patients with chronic osteomyelitis, only 55% of whom underwent surgical debridement. Cure rates based on surgical debridement were not separately reported. In contrast, Sanchez et al [149] treated 27 patients with staphylococcal osteomyelitis (25 *S. aureus*) with a higher-than-usual dose of TMP-SMX (7 mg/kg/d of trimethoprim divided into 2 or 3 daily doses) along with rifampin for a mean of 5 weeks, in addition to surgical debridement. After follow-up of 6 months to 5 years, all of the patients were cured.

Javaloyas de Morlius et al [78] reported their results with treating 37 patients with 44 episodes of osteomyelitis, 34 of which were associated with an orthopedic implant. After a week of parenteral antibiotic therapy, the patients received a median of 10 weeks of oral treatment with TMP-SMX plus rifampin (23 patients), TMP-SMX alone (5 patients), or rifampin plus ciprofloxacin (7 patients). At 2 years of follow-up, all 10 patients who had their hardware removed were cured, compared with 18 of 24 patients (75%) in whom hardware was left in place.

Stein et al [150] prescribed TMP-SMX for 6–9 months to treat 39 patients with prosthetic devices infected with MRSA. The overall success rate was 67% in the intention-to-treat population and 87% in the per-protocol population (after exclusion of 9 patients who were unable to tolerate completing the treatment). Significantly more patients who had their infected prosthetics removed were cured compared with those who did not. Likewise, de Barros et al [84] treated 60 patients with chronic osteomyelitis with TMP-SMX for 6 months, along with appropriate surgical debridement; 59 (98%) were cured after 12–60 months of follow-up. Finally, Nguyen et al [151] reported that either TMP-SMX (8 mg/kg/d) or linezolid combined with rifampin cured 79%–89% of patients with infected orthopedic implants or chronic osteomyelitis. Taken together, these data support the efficacy of high-dose TMP-SMX, the importance of concurrent surgical debridement, and the possible benefit of adjunctive rifampin therapy and prolonged therapy when treating chronic osteomyelitis, especially in patients with an associated infected implant.

Consistent with their excellent bone penetration, both fosfomycin [72, 152] and fusidic acid [156, 157], the latter preferably in combination with another anti-staphylococcal agent, have also demonstrated efficacy in treating chronic osteomyelitis. Others have summarized results of the numerous published case series describing fusidic acid combination therapy for osteomyelitis [156].
**Table 4. Cure Rates in Nonrandomized Clinical Trials for Oral Treatment of Chronic Osteomyelitis With or Without Infected Prosthesis in Adults**

| Drug | Dose (Duration) | Follow-up | Cure, % (No. of Patients) | Comment | Reference |
|------|-----------------|-----------|--------------------------|---------|-----------|
| **Fluoroquinolones** | | | | | |
| Ciprofloxacin | 500–750 mg twice daily (3–4 mo) | 1 y | 33 (12/36) | All cured patients had foreign material removed; 1/3 underwent debridement | [127] |
| Ciprofloxacin | 750 mg twice daily (3–4 mo) | 6 mo | 91 (21/23) | Cure defined as resolution or improvement | [128] |
| Ciprofloxacin | 750 mg twice daily (3 mo) | 7–21 mo | 65 (13/20) | Only 7/13 *Pseudomonas* infections cured; all debrided | [129] |
| Ciprofloxacin | 750 mg twice daily (2–4 mo) | 1–17 mo | 77 (17/22) | 4 patients who failed therapy with *Pseudomonas*; 20 debrided | [130] |
| Ciprofloxacin | 750 mg twice daily (1–6 mo) | 0–22 mo | 48 (14/29) | 7/12 *Pseudomonas* and 4/9 *Staphylococcus aureus* infections cured | [131] |
| Ciprofloxacin or nafcillin, clindamycin, or gentamicin | 750 mg by mouth twice daily (12–64 d) (ciprofloxacin); or varying doses and durations | 25–39 mo | 79 (11/14) for ciprofloxacin vs 83 (10/12) for intravenous therapy | Not randomized; patients were sequentially enrolled in the 2 arms | [132] |
| Ciprofloxacin | 200 mg intravenous twice daily, then 750 mg by mouth twice daily | ? | 67 (6/9) | Unknown duration of treatment; 5/7 *Pseudomonas* infections cured | [133] |
| Ciprofloxacin | 200 mg intravenous twice daily, then 750 mg by mouth twice daily | ? | 83 (10/12) | Unknown duration of treatment | [134] |
| Ciprofloxacin | 500–1500 mg twice daily (0.5–18 mo) | ? | 68 (30/44) | *Pseudomonas* eradicated microbiologically in 20/28 | [135] |
| **Levofloxacin** | 500 mg/d | ? | 60 (9/15) | Failure of cure in 6 patients with *S. aureus* and 1 with *Pseudomonas* infection | [136] |
| **Ofloxacin** | 400 mg/12 h intravenous for 4 doses, then 400 mg/12 h by mouth (3–6 mo) | ? | 76 (29/38) | All cured patients had foreign material removed; 1/3 underwent debridement | [137] |
| Ofloxacin | 200 mg/8–12 h (3–6 mo) | | | | |
| Ciprofloxacin | 500–750 mg/12 h (3–6 mo) | | | | |
| Ofloxacin | 200 mg 3 times daily (4–6 wk) | >6 mo | 85 (98/115) | Failure of cure in 3/15 patients with *Pseudomonas* and 5/74 with *S. aureus* infection; debridement in 113 | [138] |
| Ciprofloxacin | 750–1000 mg twice daily (3 mo) | 12 mo | 61 (19/31) | No benefit from higher dose; all had soft tissue, but not bone, debrided | [139] |
| Ofloxacin + rifampin | Ofloxacin: 200 mg 3 times daily; rifampin: 300 mg 3 times daily (both, 6–9 mo) | >6 mo | 71 (35/49) | All infections of prostheses | [140] |
| Levofoxacin + rifampin | Levofoxacin: 500 mg/d; rifampin: 600 mg/d (both, >6 wk) | >6 mo | 72 (18/25) | All had prosthetic bone implants; mean duration of therapy, 5 mo for those cured and 2.6 mo for those without cure | [141] |
| Rifampin (ofloxacin or fusidic acid) | Rifampin: 900 mg/d; ofloxacin: 200 mg 3 times daily; fusidic acid: 500 mg 3 times daily for 5 d, then twice daily (both, >6 mo) | Mean, 24 mo (range, 12–36 mo) | 55 (11/20) | All patients had orthopedic implants, only 14 of which were removed; patients were assigned to treatment arm by year of birth (ofloxacin for even years, fusidic acid for odd years) | [142] |
Table 4 continued.

| Drug | Dose (Duration)\(^a\) | Follow-up | Cure,\(^b\) % (No. of Patients) | Comment | Reference |
|------|-----------------------|-----------|-------------------------------|---------|-----------|
| **Other Agents** | | | | | |
| Rifampin + various other antibiotics | 600 mg/d (6 mo) | Variable | 50 (7/14) | All cases refractory to prior therapy | [101] |
| Rifampin + quinolone vs other antibiotics | When used, rifampin at 20 mg/kg, divided into 2 daily doses (not to exceed 1800 mg/d) | Mean, 44 ± 32 mo | 98 (37/39) vs 68 (40/59) | All patients had S. aureus prosthetic joint infections; 29 received rifampin in combination with nonquinolone antibiotics; in multivariate analysis, rifampin-quinolone combination had an odds ratio of 0.4 (95%, CI 0.17–0.97) for failure | [143] |
| Rifampin + levofloxacin (prospective) vs historical cohort with variable antibiotics, without or with rifampin | When used, rifampin at 900 mg/d (3–6 mo) | ? | 93 (13/14) (prospective) vs 63 (34/56) (historical without rifampin) vs 68 (21/31) (historical with rifampin) | All had retained prosthetic joints; by multivariate analysis, hazard ratio for treatment failure was 1.0 for historical cohort without rifampin, 0.55 (95%, CI 0.25–1.26) for historical cohort with rifampin, 0.11 (95%, CI 0.01–0.84) for prospective rifampin cohort (\(P = .03\)) | [144] |
| **Linezolid** | 600 mg/12 h | ? | 60 (45/89) | Compassionate use program | [145] |
| Clindamycin | 50–150 mg/6 h (mean, 16 wk) | Variable | 42 (5/12) | ... | [146] |
| TMP-SMX | 1–2 DS tablet twice daily | ? | 83 (5/6) | No patients had debridement | [147] |
| TMP-SMX | 1 DS tablet twice daily (4–8 wk) | 11–70 mo | 45 (30/66) | 55% of patients had debridement | [148] |
| TMP-SMX + rifampin | TMP: 3.5 mg/kg twice daily; rifampin: 600–1200 mg/d (mean, 5 wk for both) | 6 mo to 5 y | 100 (27/27) | All patients had debridement | [149] |
| TMP-SMX with or without rifampin | DS tablet twice daily; rifampin: 300–450 mg twice daily (median, 10 wk for both) | 2 y | 82 (28/34) | 10 patients had debridement, all of whom were cured | [78] |
| TMP-SMX | TMP: 5 mg/kg twice daily (6–9 mo) | 24–75 mo | 67 (26/39) | 11 patients had device removed | [150] |
| TMP-SMX | Dose unclear (6 mo) | 12–60 mo | 98 (59/60) | All patients had debridement | [84] |
Randomized Clinical Trials

There have been few randomized trials of systemic therapy for ostemyelitis in adults. A systematic review published in 2009 found only 8 small trials, with a total of 228 evaluable subjects [158]. A composite analysis of the 5 trials that compared oral with parenteral treatment found no significant difference in remission rate at 12 months of follow-up, but the rate of moderate or severe adverse events was significantly higher with parenteral than with oral agents (15.5% vs 4.8%, respectively).

Adjunctive rifampin therapy has been studied in 2 randomized clinical trials of patients with chronic ostemyelitis caused by S. aureus [159, 160] (Table 5). Summarizing their results, more patients who received rifampin in addition to other antibiotics were cured compared with those who did not (17 of 20 [85%] vs 12 of 21 [57%]; P < .05 by Fisher's exact test), and no patient terminated therapy due to rifampin-related adverse effects. In another trial, Zimmerli et al [163] randomized patients with prosthetic devices infected with Staphylococcus spp. to receive either rifampin or placebo, plus ciprofloxacin, for 3–6 months. In the per-protocol population, cure rates were 100% for rifampin-treated versus 58% for placebo-treated patients (P < .02). Of note, the causative pathogen in 4 of the 5 patients whose infection failed to respond to ciprofloxacin monotherapy developed resistance to ciprofloxacin.

Six studies randomized patients with chronic ostemyelitis to receive either an oral fluorquinolone (ciprofloxacin in 3 [164–166], ofloxacin in 3 [167–169]) or standard intravenous therapy (Table 5). In all, cure rates were similar for those treated with oral and intravenous therapy. Finally, Falta et al [170] randomized 50 patients with chronic ostemyelitis caused by methicillin-sensitive S. aureus to treatment with intravenous therapy. Two of the 5 patients whose infection failed to respond to ciprofloxacin monotherapy developed resistance to ciprofloxacin.

Clinical Practice

CONCLUSIONS

Assessing treatments of chronic ostemyelitis is confounded by several factors, including the difficulty in diagnosing the condition or establishing a microbiological etiology, the presence of necrotic bone in most (and prosthetic implants in many) patients, and the lack of a consensus definition of cure. Nevertheless, we draw several conclusions from available published studies.

### Table 4 continued.

| Drug |
|---|
| TMP-SMX or linezolid + rifampin |
| Dose (Duration) |
| TMP: 8 mg/kg; linezolid: 600 mg twice daily; rifampin: 10 mg/kg twice daily (all given intravenously for 1 wk and then by mouth) |
| Follow-up |
| ≥12 mo |
| Cure, % (No. of Patients) |
| 89 (37/41) |
| Comment |
| 20 patients with chronic ostemyelitis and 56 with orthopedic implant infections; mean treatment durations were 15 wk (range, 1–53 wk) for TMP-SMX-based therapy and 18 wk (8–36 wk) for linezolid-based therapy; adverse event rates were similar (46% vs 43%), as were discontinuation rates (14% vs 21%) |
| Reference |
| [151] |

| Fosfomycin |
| 10 g once, then 5 g 3 times daily |
| 5–28 d |
| 47 (29/60) |
| Outcome defined as "very good"; mean follow-up, 37 mo |
| Reference |
| [72] |

| Fosfomycin |
| 4–8 g/d intravenous or by mouth |
| 78 (29/37) |
| 23 patients had debridement |
| Reference |
| [152] |

Abbreviations: CI, confidence interval; DS, double-strength; TMP-SMX, trimethoprim-sulfamethoxazole.

a Drugs were administered orally unless otherwise specified.

b Definitions of cure varied among the studies.

c This was a randomized study of ciprofloxacin at 750 vs 1000 mg twice daily. Because no comparator therapy was used, it is included in the nonrandomized study category.
| Drug                      | Dose (Duration)                                                                 | Follow-up | Cure, a % (No. of Patients) | Comment                                                                 | Reference |
|---------------------------|--------------------------------------------------------------------------------|-----------|----------------------------|-------------------------------------------------------------------------|-----------|
| Ceftazidime vs ticarcillin + tobramycin | Ceftazidime: 2 g/12 h intravenous; ticarcillin: 3 g/4 h intravenous; tobramycin: 1.5 mg/kg/8 h intravenous (mean, 35 d; range, 26–63 d) | 2–31 mo   | 67 (6/9) vs 100 (9/9)      | Open label; all patients had debridement                                | [161]     |
| Vancomycin or oxacillin + (rifampin vs pyridium placebo) | Vancomycin: 1 g/12 h intravenous; oxacillin: 3 g/6 h intravenous; rifampin: 600 mg/d by mouth | ?         | 90 (9/10) vs 62 (8/13)     | Double-blind study                                                      | [159]     |
| Nafcillin vs (nafcillin + rifampin) | Nafcillin: 20 mg/kg/4 h intravenous; rifampin: 600 mg/12 h by mouth (mean, 6 wk) | 9–36 mo   | 80 (8/10) vs 50 (4/8)      | Open label; 16 patients had debridement                                 | [160]     |
| Linezolid vs (ampicillin-sulbactam or amoxicillin-clavulanate) | Linezolid: 600 mg twice daily, by mouth or intravenous; ampicillin-sulbactam: 1.5–3 g/6 h intravenous; amoxicillin-clavulanate: 500–875 mg by mouth 2 or 3 times daily | ?         | 61 (27/44) vs 69 (11/16)   | Open label; part of larger trial of diabetic patients with soft-tissue infections; patients requiring >4 wk of therapy were excluded | [162]     |
| Ciprofloxacin + (rifampin vs placebo) | Ciprofloxacin: 750 mg by mouth twice daily; rifampin: 450 mg by mouth twice daily (3–6 mo) | Median, 3 y | 100 (12/12) vs 58 (7/12)   | Double-blind study                                                      | [163]     |
| Ciprofloxacin vs “appropriate antimicrobial therapy” | 750 mg by mouth twice daily (treatment for ≥6 wk) | ?         | 50 (7/14) vs 69 (11/16)    | For patients infected with *Pseudomonas,* cure rate were 3/8 for ciprofloxacin vs 7/9 for comparator antibiotics | [164]     |
| Ciprofloxacin vs ceftazidime | Ciprofloxacin: 200 mg intravenous twice daily, then 500 mg by mouth twice daily; ceftazidime: 2 g/12 h intravenous | ?         | 67 (2/3) vs 100 (3/3)      | Part of larger study of serious gram-negative infections; open label    | [165]     |
| Ciprofloxacin vs (ceftazidime or nafcillin + amikacin) | Ciprofloxacin: 750 mg by mouth twice daily; other antibiotics: ? doses (mean, 8 wk) | 1 y       | 77 (24/31) vs 79 (22/28)   | Open label; all patients had debridement                                | [166]     |
| Ciprofloxacin vs lomefloxacin | Ciprofloxacin: 750 mg by mouth twice daily; lomefloxacin: 800 mg by mouth twice daily | Median, 8 mo (range, 0–36 mo) | 40 (2/5)                   | Open label; 5 failures with ofloxacin were due to infections with *Pseudomonas (n = 2)* or *Staphylococcus aureus (n = 3)* | [167]     |
| Ofloxacin vs (ceftazidime or cefazolin) | Ofloxacin: 400 mg by mouth twice daily (mean, 8 wk); ceftazidime: 2 g/12 h intravenous (mean, 4 wk); cefazolin: 1 g/8 h intravenous (mean, 4 wk) | Mean, 1.5 y | 74 (14/19) vs 86 (12/14)   | Open label; part of larger study of soft-tissue foot infections in diabetic patients | [168]     |
| Ofloxacin vs ampicillin-sulbactam followed by amoxicillin-clavulanate | Ofloxacin: 400 mg by mouth twice daily; ampicillin-sulbactam: 1–2 g/6 h intravenous; amoxicillin-clavulanate: 500 mg by mouth 3 times daily | 3–4 wk    | 39 (6/16) vs 20 (1/5)      | Open label                                                              | [169]     |
| Ofloxacin vs imipenem | Ofloxacin: 400 mg by mouth twice daily; imipenem: 500 mg/6 h intravenous | ?         | 69 (11/16) vs 50 (8/16)    | All patients had debridement                                            | [167]     |
| Cloxacillin vs (TMP-SMX + rifampin) | Cloxacillin: 2 g/4 h intravenous; TMP: 7–8 mg/kg by mouth twice daily; rifampin: 600 mg/d by mouth (8 wk) | Mean, 10 y | 90 (19/21) vs 89 (24/27)   | Open label; all patients had debridement                                | [170]     |

Abbreviation: TMP-SMX, trimethoprim-sulfamethoxazole.

* Definitions of cure varied by study.
First, oral antibiotic therapy with highly bioavailable agents is an acceptable alternative to parenteral therapy. The widely held preference for parenteral therapy for chronic osteomyelitis is based more on custom than evidence. There are actually fewer published studies of parenteral than oral therapy for osteomyelitis, and success rates are consistently similar for both routes. Furthermore, oral therapy is generally simpler for the patient, avoids risks associated with intravenous catheters, and is less expensive. Preferred oral agents, based on both pharmacokinetic and clinical data, include fluoroquinolones or TMP-SMX, which achieve high cure rates when administered for 8–16 weeks, particularly in the context of concomitant surgical debridement. We would like to see studies of shorter durations of treatment (eg, 4–6 weeks) to determine whether they produce similar results. It may be advisable to use higher-than-usual doses (eg, ciprofloxacin at 750 mg twice daily and TMP-SMX at 7–10 mg/kg/d of trimethoprim) when treating chronic osteomyelitis. Because gram-positive cocci have a high propensity to develop resistance during fluoroquinolone therapy [171], the reported relapses of staphylococcal osteomyelitis after ciprofloxacin or ofloxacin treatment are not surprising. Therefore, TMP-SMX and probably clindamycin are preferable for treating osteomyelitis caused by gram-positive cocci. Other options for selected cases could include linezolid or doxycycline, although toxicity with prolonged treatment limits use of the former agent, and no clinical data are available for the latter. For anaerobic osteomyelitis, oral metronidazole is the agent of choice, given its outstanding bone penetration and efficacy in case reports. Although the theory is still being debated, there is no evidence that bactericidal agents are superior to bacteriostatic in the treatment of osteomyelitis [172].

Second, adding rifampin to a variety of antibiotic regimens has been shown to improve the cure rates in: (1) animal models, (2) retrospective studies in humans, and (3) randomized clinical trials of chronic osteomyelitis and orthopedic implant infections. Hence, clinicians should consider adjunctive rifampin therapy (ie, combined with another active agent) for patients who are able to tolerate it and who do not require concomitant treatment with drugs with which it is likely to interact.

Third, clinicians must individualize the duration of antibiotic therapy based on the patient’s clinical and radiographic response, with continued monitoring after cessation of therapy. No strong evidence supports the standard recommendation of 4–6 weeks of therapy after surgical debridement [4], nor is there evidence that more prolonged therapy further improves cure rates. Unfortunately, there are no well established markers of successful treatment and relapse rates remain substantial, even after prolonged antibiotic therapy. Defining the optimal duration of therapy for chronic osteomyelitis is an area of urgent need.

Fourth, surgical resection of necrotic and infected bone, in conjunction with antibiotic therapy, appears to increase the cure rate of chronic osteomyelitis. However, not all cases of chronic osteomyelitis require surgical debridement for cure, and we need studies to clarify which may and which may not. We need comparative effectiveness studies to answer these and a number of other questions regarding therapy of chronic osteomyelitis.

Note

Potential conflicts of interest. B. S. has received clinical trial grant/contract support from Gilead, Astellas, Novartis, and Cubist and consulting fees from GlaxoSmithKline, Pfizer, Basilea, The Medicines Company, Achaogen, Eisai, Meli, and Polymedix. B. A. L. has received grant support or provided consultation to the following: Pfizer, Merck, Cubist, and Johnson & Johnson.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Moodie RL. Osteomyelitis in the Permian. Science 1921; 53:333.
2. Norden CW. Lessons learned from animal models of osteomyelitis. Rev Infect Dis 1988; 10:103–10.
3. Waldvogel FA, Papageorgiou PS. Osteomyelitis: the past decade. N Engl J Med 1980; 303:360–70.
4. Haidar R, Der Boghossian A, Atyieh B. Duration of post-surgical antibiotics in chronic osteomyelitis: empiric or evidence-based? Int J Infect Dis 2010; 14:e752–8.
5. Al-Majiah M, Hemmady MV, Shoib A, Morgan-Jones RL. Recurrence of chronic osteomyelitis in a regenerated fibula after 65 years. Orthopedics 2007; 30:403–4.
6. Donati L, Quadri P, Reiner M. Reactivation of osteomyelitis caused by Staphylococcus aureus after 50 years. J Am Geriatr Soc 1999; 47:1035–7.
7. West WF, Kelly PJ, Martin WJ. Chronic osteomyelitis. I. Factors affecting the results of treatment in 186 patients. JAMA 1970; 213:1837–42.
8. Gallie WE. First recurrence of osteomyelitis eighty years after infection. J Bone Joint Surg Br 1951; 33-B:110–1.
9. Ciampolini J, Harding KD. Pathobiology of chronic bacterial osteomyelitis: why do antibiotics fail so often? Postgrad Med J 2000; 76:479–83.
10. Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects, N Engl J Med 1970; 282:198–206.
11. Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects (second of three parts). N Engl J Med 1970; 282:260–6.
12. Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. 3. Osteomyelitis associated with vascular insufficiency. N Engl J Med 1970; 282:316–22.
13. Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis 2001; 1:175–88.
14. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis 2005; 9:127–38.
15. Rod-Fleury T, Dunkel N, Assal M, et al. Duration of post-surgical antibiotic therapy for adult chronic osteomyelitis: a single-centre experience. Int Orthop 2011; 35:1725–31.
16. Wewalka G, Endler M, Kraft A. Antibiotic concentrations in wound secretions and bone during the simultaneous administration of mezlocillin and oxacillin. Infection 1982; 10(Suppl 3):S213–6.
17. Warnke JP, Wildfeuer A, Eibel G, Pfaff G, Klammer A. Pharmacokinetics of ampicillin/sulbactam in patients undergoing spinal micro-neurosurgical procedures. Int J Clin Pharmacol Ther 1998; 36:253–7.

18. Wildfeuer A, Mallwitz J, Goethhardt H, et al. Pharmacokinetics of ampicillin, sulbactam and cefotiam in patients undergoing orthopedic surgery. Infection 1997; 25:258–62.

19. Cunha BA, Gossling HR, Pasternak HS, Nightingale CH, Quintiliani R. Penetration of cephalosporins into bone. Infection 1984; 12:80–4.

20. Polk R, Hume A, Kline BJ, Cardea J. Penetration of moxalactam and cefazolin into bone following simultaneous bolus or infusion. Clin Orthop 1983; 177:216–21.

21. Williams DN, Gustilo RB, Beverly R, Kind AC. Bone and serum concentrations of five cephalosporin drugs. Relevance to prophylaxis and treatment in orthopedic surgery. Clin Orthop 1983; 179:253–65.

22. Schurman DJ, Hirshman HP, Kajiyama G, Moser K, Burton DS. Cefazolin concentrations in bone and synovial fluid. J Bone Joint Surg Am 1978; 60:359–62.

23. Fass RJ. Treatment of osteomyelitis and septic arthritis with cefazolin. Antimicrob Agents Chemother 1978; 13:405–11.

24. Graziani AL, Lawson LA, Gibson GA, Steinberg MA, MacGregor RR. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 1988; 32:1320–2.

25. Traunmuller F, Schintler MV, Metzler J, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 2010; 65:1252–7.

26. Lovering AM, Walsh TR, Bannister GC, MacGowan AP. The penetration of ceftriaxone and cefamandole into cancellous and cortical bone tissues. J Antimicrob Chemother 1998; 25:258–62.

27. Soudry B, Sirot J, Lopitaux R, Dumont C, Delisle JJ, Parenton M. Diffusion of ceftriaxone in human bone tissue. Pathol Biol (Paris) 1986; 34:58–63.

28. Scaglione F, De Martini G, Peretto L, et al. Pharmacokinetic study of cefodizime and ceftriaxone in sera and bones of patients undergoing hip arthroplasty. Antimicrob Agents Chemother 1997; 41:2492–4.

29. Raymakers JT, Schaper NC, van der Heyden JJ, Tordoir JH, Kitslaar PJ. Penetration of ceftazidime into bone from severely ischaemic limbs. J Antimicrob Chemother 1998; 42:543–5.

30. Leigh DA, Griggs J, Tighe CM, et al. Pharmacokinetic study of ceftriaxone in bone and serum of patients undergoing hip and knee arthroplasty. J Antimicrob Chemother 1985; 16:837–42.

31. Handa N, Kawakami T, Kitaoka K, et al. The clinical efficacy of imipenem/cilastatin sodium in orthopedic infections and drug levels in the bone tissue. Jpn J Antibi 1997; 50:622–7.

32. Breilh D, Boselli E, Bel JC, Chassard D, Saux MC, Allauochiche B. Diffusion of cepafirme into cancellous and cortical bone tissue. J Chemother 2004; 18:335–40.

33. Wittmann DH, Kuipers TH, Fock R, Holl M, Bauernfeind A. The parenteral kinetics of ampicillin/sulbactam in man. Int J Clin Pharmacol Res 1985; 5:79–86.

34. Wildfeuer A, Schwiersch U, Engel K, et al. Pharmacokinetics of sulbactam and ampicillin intravenously applied in combination to healthy volunteers and patients: determination of the ratio of the two drugs in serum and in various tissues. Arzneimittelforschung 1988; 38:1640–3.

35. Quintiliani R, Nightingale CH. Cefazolin. Ann Intern Med 1978; 89:650–6.

36. Garcia I, Fainstein V, Smith RG, Bodey GP. Multiple-dose pharmacokinetics of ceftazidime in cancer patients. Antimicrob Agents Chemother 1983; 24:141–4.

37. Standiford HC, Drusano GL, Bustamante CI, et al. Imipenem co-administered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. Antimicrob Agents Chemother 1986; 29:412–7.

38. Paradis D, Valee F, Allard S, et al. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob Agents Chemother 1992; 36:2085–92.

39. Signs SA, Tan JS, Salstrom SJ, File TM. Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration. Antimicrob Agents Chemother 1992: 36:1400–3.

40. Raymakers JT, Houben AJ, van der Heyden JJ, Tordoir JH, Kitslaar PJ, Schaper NC. The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb. Diabet Med 2001; 18:229–34.

41. Massias L, Dubois C, de Lentecker P, Brodaty O, Fischer M, Farinotti R. Penetration of vancomycin in uninfected sternal bone. Antimicrob Agents Chemother 1992; 36:2539–41.

42. Martin C, Alaya M, Mallet MN, et al. Penetration of vancomycin into mediastial and cardiac tissues in humans. Antimicrob Agents Chemother 1994; 38:396–9.

43. Holtom PD, Zalavars CG, Lamp KC, Park N, Friedrich LV. Clinical experience with daptomycin treatment of foot or ankle osteomyelitis: a preliminary study. Clin Orthop Relat Res 2007; 461:35–9.

44. Fong IW, Ledbetter WH, Vandenbroucke AC, Simbul M, Rahman V. Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicrob Agents Chemother 1986; 29:405–8.

45. Meissner A, Borner K. Concentration of ciprofloxacin in bone tissue. Aktuelle Traumatol 1993; 23:80–4.

46. Wacha H, Wagner D, Schafer V, Knothe H. Concentration of ciprofloxacin in bone tissue after single parenteral administration to patients older than 70 years. Infection 1990; 18:173–6.

47. von Baum H, Bottcher S, Abel R, Gerner JH, Sonntag HG. Tissue and serum concentrations of levofloxacin in orthopaedic patients. Int J Antimicrob Agents 2001; 18:335–40.

48. Rimmelle T, Boselli E, Breilh D, et al. Diffusion of levofloxacin into bone and synovial tissues. J Antimicrob Chemother 2004; 53:533–5.

49. Fong IW, Rittenhouse BR, Simbul M, Vandenbroucke AC. Bone penetration of enoxacin in patients with and without osteomyelitis. Antimicrob Agents Chemother 1998; 32:834–7.

50. Malincarne L, Ghebregzabher M, Moretti MV, et al. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. J Antimicrob Chemother 2006; 57:950–4.

51. Kutscha-Lissberg F, Hebler U, Muhr G, Koller M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother 2003; 47:3964–6.

52. Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoema of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50:747–50.
82. Dworkin R, Modin G, Kunz S, Rich R, Zak O, Sande M. Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. Antimicrob Agents Chemother 1990; 34:1014–16.
83. Iversen P, Nielsen OS, Jensen KM, Madsen PO. Comparison of concentrations of rifampin and a new rifamycin derivative, DI, 473, in canine bone. Antimicrob Agents Chemother 1983; 23:338–40.
84. de Barros JW, Calapodopoulos CJ, Oliveira DJ, Miki Junior P. The treatment of chronic osteomyelitis. Rev Soc Bras Med Trop 1992; 25:235–9.
85. Norden CW, Shaffer M. Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with vancomycin and rifampin. J Infect Dis 1983; 147:352–7.
86. Yu VL, Zuravleff JJ, Peacock JE, DeHertogh D, Tashjian L. Addition of rifampin to carboxyphenilin-aminoglycoside combination for the treatment of Pseudomonas aeruginosa infection: clinical experience with four patients. Antimicrob Agents Chemother 1984; 26:575–7.
87. Zuravleff JJ, Chervenick P, Yu VL, Muder RR, Diven WF. Addition of rifampin to ticarcillin-tobramycin combination for the treatment of Pseudomonas aeruginosa infections: assessment in a neutropenic mouse model. J Lab Clin Med 1984; 103:878–85.
88. Chang HR, Vladoianu IR, Pechere J. Effects of ampicillin, ceftriaxone, chloramphenicol, pefloxacin and trimethoprim-sulphamethoxazole on Salmonella typhi within human monocyte-derived macrophages. J Antimicrob Chemother 1990; 26:689–94.
89. Close SJ, McBurney CR, Garvin CG, Chen DC, Martin SJ. Trimethoprim-sulfamethoxazole activity and pharmacodynamics against glycopeptide-intermediate Staphylococcus aureus. Pharmacotherapy 2002; 22:983–9.
90. Yeldandi V, Strodtman R, Lentinio JR. In-vitro and in-vivo studies of trimethoprim-sulfamethoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother 1988; 22:873–80.
91. Burman LG. The antimicrobial activities of trimethoprim and sulfonamides. Scand J Infect Dis 1969; 18:146–51.
92. Centers for Disease Control and Prevention (CDC). Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections–Los Angeles County, California, 2002–2003. MMWR Morb Mortal Wkly Rep 2003; 52:88.
93. Eady EA, Cove JH. Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus—an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis 2003; 16:103–24.
94. Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002; 21:530–4.
95. Bancroft E, Kilgore G, Jones A, et al. Four outbreaks of community-associated methicillin-resistant Staphylococcus aureus in Los Angeles County, California, 2002–2003. MMWR Morb Mortal Wkly Rep 2003; 52:88.
96. Forti G, Benincori C. Doxycycline and the teeth. Lancet 1969; 1:782.
97. Chazan B, Strahalievitz J, Millgram MA, Kaufmann S, Raz R. Bacteroides fragilis vertebral osteomyelitis secondary to anal dilatation. Spine (Phila Pa 1976) 1992; 17:35–41.
98. Riley TV, Karthigasu KT. Chronic osteomyelitis due to Clostridium difficile. Br Med J (Clin Res Ed) 1982; 284:1217–8.
99. Melo JC, Raff MJ, Wunderlich HF, Chua CH, Summersgill JT, Varghese R. Metronidazole treatment of Bacteroides fragilis infections. Am J Med Sci 1980; 280:143–9.
100. Zimmerman J, Silver J, Shapiro M, Friedman G, Melmed RN. Clindamycin unresponsive anaerobic osteomyelitis treated with oral metronidazole. Scand J Infect Dis 1980; 12:79–80.
101. Norden CW, Fierer J, Bryant RE. Chronic staphylococcal osteomyelitis: treatment with regimens containing rifampin. Rev Infect Dis 1983; 5(Suppl 3):S495–501.
102. Pelouquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 1997; 41:2670–9.
103. Acocella G. Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis 1983; 5(Suppl 3):S428–32.
104. Reeves DS. The pharmacokinetics of fusidic acid. J Antimicrob Chemother 1987; 20:467–76.
105. O’Reilly T, Kunz S, Sande E, Zak O, Sande MA, Tauber MG. Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin. Antimicrob Agents Chemother 1992; 36:2693–7.
106. Mader JT, Reinarz JA, LeFrock JL. Cefotaxime treatment in patients with osteomyelitis and septic arthritis: a multicenter study. Clin Ther 1982; 5(Suppl A):10–8.
107. LeFrock JL, Carr BB. Clinical experience with cefotaxime in the treatment of serious bone and joint infections. Rev Infect Dis 1982; 4(Suppl):S465–71.
108. MacGregor RR, Gentry LO. Imipenem/cilastatin in the treatment of osteomyelitis. Am J Med 1985; 78:100–3.
109. Bach MC, Cocchietto DM. Cefazidime as single-agent therapy for gram-negative aerobic bacillary osteomyelitis. Antimicrob Agents Chemother 1987; 31:1605–8.
110. Gomis M, Herranz A, Aparicio P, Filloy JL, Pastor J. Cefotaxime in the treatment of chronic osteomyelitis caused by gram-negative bacilli. J Antimicrob Chemother 1990; 26(Suppl A):45–52.
111. Simons WJ, Lee TJ. Aztreonam in the treatment of bone and joint infections caused by gram-negative bacilli. Rev Infect Dis 1985; 7(Suppl 4):S783–8.
112. Conrad DA, Williams RR, Couchman TL, Lentnek AL. Efficacy of ofloxacin in the treatment of osteomyelitis caused by Pseudomonas aeruginosa. Rev Infect Dis 1991; 13(Suppl 7):S634–9.
113. Lucht RF, Fresard A, Berthelot P, et al. Prolonged treatment of chronic Pseudomonas aeruginosa osteomyelitis with a combination of two effective antibiotics. Infection 1994; 22:276–80.
114. Akova M, Ozcele O, Gullu I, et al. Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections. J Chemother 1996; 8:284–9.
115. Munchhof WJ, Carney J, Neilson G, et al. Continuous infusion of ticarcillin-clavulnate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2005; 25:514–22.
116. Legout L, Senneville E, Stern R, et al. Treatment of bone and joint infections caused by gram-negative bacilli with a cepafime-fluoroquinolone combination. Clin Microbiol Infect 2006; 12:1030–3.
117. Dombrowski JC, Winston LG. Clinical failures of appropriately treated methicillin-resistant Staphylococcus aureus infections. J Infect 2008; 57:110–5.
118. Livorsi DJ, Daver NG, Atmar RL, Sheiburne SA, White AC Jr, Musher DM. Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. J Infect 2008; 57:128–31.
119. Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant gram-positive bone and joint infections. Curr Med Res Opin 2005; 21:1923–6.
120. Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med 2007; 120(10 Suppl 1):S13–20.
121. Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 2003; 114:723–8.
122. Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 2003; 51:1261–8.
123. Schafer JJ, Mangino JE. Multidrug-resistant Acinetobacter baumannii osteomyelitis from Iraq. Emerg Infect Dis 2008; 14:512–4.
124. Chen PL, Yan JH, Wu CJ, et al. Salvage therapy with tigecycline for recurrent infection caused by etanercept-resistant extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2010; 68:312–4.
125. Kuo SC, Wang FD, Fung CP, et al. Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients. J Microbiol Immunol Infect 2011; 44:45–51.
126. Darley ES, MacGowan AP. Antibiotic treatment of gram-positive bone and joint infections. J Antimicrob Chemother 2004; 53:928–35.
127. Nix DE, Cumbo TJ, Kuritzky P, DeVito JM, Schentag JJ. Oral ciprofloxacin in the treatment of serious soft tissue and bone infections: efficacy, safety, and pharmacokinetics. Am J Med 1987; 82:146–53.
128. Lesse AI, Freer C, Salata RA, Francis JB, Scheld WM. Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis. Am J Med 1987; 82:247–53.
129. Gilbert DN, Tice AD, Marsh PK, Craven PC, Preheim LC. Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli. Am J Med 1987; 82:254–8.
130. Hessen MT, Ingerman MJ, Kaufman DH, et al. Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis. Am J Med 1987; 82:262–5.
131. Greenberg RN, Kennedy DJ, Reilly PM, et al. Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. Antimicrob Agents Chemother 1987; 31:151–5.
132. Mader JT, Cantrell JS, Calhoun J. Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. J Bone Joint Surg Am 1990; 72:104–10.
133. Giamarelou H, Galanakis N. Use of intravenous ciprofloxacin in difficult-to-treat infections. Am J Med 1987; 82:346–51.
134. Scully BE, Neu HC. Treatment of serious infections with intravenous ciprofloxacin. Am J Med 1987; 82:369–75.
135. Therapy of acute and chronic gram-negative osteomyelitis with ciprofloxacin: report from a Swedish Study Group. J Antimicrob Chemother 1988; 22:221–8.
136. Greenberg RN, Newman MT, Shariaty S, Pectol RW. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrob Agents Chemother 2000; 44:164–6.
137. Dellamonica P, Bernard E, Et esse H, Garraffo R, Drugeon HB. Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 1989; 8:1024–30.
138. Ketterl R, Beckurts T, Stubinger B, Claudi B. Use of ofloxacin in open fractures and in the treatment of post-traumatic osteomyelitis. J Antimicrob Chemother 1989; 22(Suppl C):139–66.
139. Petersen LR, Lissack LM, Canter K, Fasching CE, Clabots C, Gerding DN. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am J Med 1989; 86:801–8.
140. Drancourt M, Stein A, Argenson JN, Zannier A, Curvale G, Raoul DT. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother 1993; 37:1214–8.
141. Barberan J, Aguilar L, Gimenez MJ, Carroquino G, Granizo JJ, Prieto J. Levofloxacin plus rifampicin conservative treatment of 25 early staphylococcal infections of osteosynthetic devices for rigid internal fixation. Int J Antimicrob Agents 2008; 32:154–7.
142. Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Gerding DN. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997; 39:235–40.
143. Senneville E, Joulie D, Legout L, et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis 2011; 53:334–40.
144. El Helou OC, Berbari EF, Lahr BD, et al. Efficacy and safety of rifampin containing regimens for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis 2010; 29:961–7.
145. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36:159–68.
146. Pontifex AH, McNaught DR. The treatment of chronic osteomyelitis with clindamycin. Can Med Assoc J 1973; 109:105–7.

147. Craven JL, Pugley DJ, Blowers R. Trimethoprim-sulphamethoxazole in acute osteomyelitis due to penicillin-resistant staphylococci in Uganda. Br Med J 1970; 3:201–3.

148. Saeengnipanthkul S, Pongvivat T, Mahaisavariya B, Laupattarakasem W. Co-trimoxazole in the treatment of chronic osteomyelitis. J Med Assoc Thai 1988; 71:186–91.

149. Sanchez C, Matamala A, Salavert M, et al. Cotrimoxazole plus rifampicin in the treatment of staphylococcal osteoarticular infection. Enferm Infec Microbiol Clin 1997; 15:10–3.

150. Stein A, Bataille JF, Drancourt M, et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998; 42:3086–91.

151. Nguyen S, Pasquet A, Legout L, et al. Efficacy and tolerance of rifampicin-linezolid combined with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect 2009; 15:1163–9.

152. Fernandez-Valencia JE, Sahak T, Canedo T, Olay T. Fosfomycin in osteomyelitis. Chemotherapy 1976; 22:121–34.

153. Papasian CJ, McGregor DH, Hodges GR, Kennedy J. Peptostreptococcal vertebral osteomyelitis. J Clin Microbiol 1986; 24:633–5.

154. Seto BG, Lynch SR, Moy PK. Chronic osteomyelitis of mandible caused by penicillin-resistant Bacteroides ruminicola. Report of a case. Oral Surg Oral Med Oral Pathol 1986; 61:29–31.

155. Edmondson HT. Parenteral and oral clindamycin therapy in surgical infections: a preliminary report. Ann Surg 1973; 178:637–42.

156. Atkins B, Gottlieb T. Fusidic acid in bone and joint infections. Int J Antimicrob Agents 1999; 12(Suppl 2):S79–93.

157. Wolfe CR. Case report: treatment of chronic osteomyelitis. Clin Infect Dis 2011; 52(Suppl 7):S338–41.

158. Conterno LO, da Silva Filho CR. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev 2009; (3):CD004439.

159. Van der Auwera P, Klastersky J, Thys JP, Meunier-Carpentier F, Legrand JC. Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother 1985; 28:467–72.

160. Norden CW, Bryant R, Palmer D, Montgomerie JZ, Wheat J. Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 1986; 79:947–51.

161. Sheftel TG, Mader JT. Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli. Antimicrob Agents Chemother 1986; 29:112–5.

162. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004; 38:17–24.

163. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279:1537–41.

164. Greenberg RN, Tice AD, Marsh PK, et al. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis. Am J Med 1987; 82:266–9.

165. Peacock JE Jr, Pegram FS, Weber SE, Leone PA. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. Am J Med 1989; 87:1855–905.

166. Gentry LO, Rodriguez GG. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother 1990; 34:40–3.

167. Gentry LO, Rodriguez-Gomez G. Ofloxacin versus parenteral imipenem for chronic osteomyelitis. Antimicrob Agents Chemother 1991; 35:538–41.

168. Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin Infect Dis 1997; 24:643–8.

169. Gomis M, Barberan J, Sanchez B, Khorrami S, Borja J, Garcia-Barbal J. Oral ofloxacin versus parenteral imipenem-cilastatin in the treatment of osteomyelitis. Rev Esp Quimioter 1999; 12:244–9.

170. Euba G, Murillo O, Fernandez-Sabe N, et al. Long-term follow-up of orally rifampin–cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother 2009; 53:2672–6.

171. Schnitz FJ, Fluit AC, Hafner D, et al. Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2000; 44:3228–31.

172. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin Infect Dis 2004; 38:864–70.